Nordic Nanovector to Present at Upcoming Jefferies Virtual Healthcare Conference and ABG Sundal Collier Virtual Oncology Seminar

Oslo, Norway, 2 June 2020

Nordic Nanovector ASA (OSE: NANO) announces that members of its management team will present at Jefferies Virtual Healthcare Conference, taking place 2-4 June 2020.

Nordic Nanovector will also present at ABG Sundal Collier Virtual Oncology Seminar 10 June 2020.

Presentations details are as follows:

Jefferies Virtual Healthcare Conference
Date: Tuesday, 2 June 2020
Time: 16:30 CET

ABG Sundal Collier Virtual Oncology Seminar
Date: Wednesday, 10 June 2020
Time: 10:25 CET

The company presentation will be available on Nordic Nanovector’s Investors and Media page at the same time.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin^®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin^® and intends to actively participate in the commercialisation of Betalutin^® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.